In view of clinical translation, EGFR-targeted NB-PDT has already been proven to be effective and selective using patient-derived HNSCC organoids and corresponding normal tissue organoids derived from the same patient [8]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.